%0 Journal Article
%T Development of Budesonide Loaded Biopolymer Based Dry Powder Inhaler: Optimization, In Vitro Deposition, and Cytotoxicity Study
%A Ashwin J. Mali
%A Atmaram P. Pawar
%A Ravindra N. Purohit
%J Journal of Pharmaceutics
%D 2014
%I Hindawi Publishing Corporation
%R 10.1155/2014/795371
%X The progress in the development of DPI technology has boosted the use of sensitive drug molecules for lung diseases. However, delivery of these molecules from conventional DPI to the active site still poses a challenge with respect to deposition efficiency in the lung. At same time, serious systemic side effects of drugs have become a cause for concern. The developed budesonide loaded biopolymer based controlled release DPI had shown maximum in vitro lung deposition with least toxicity. The subject of present study, lactose-free budesonide loaded biopolymer based DPI, further corroborates the great potential of antiasthmatic drugs. This technology is expected to revolutionize the approaches towards enhanced therapeutic delivery of prospective drugs. 1. Introduction Corticosteroids have been found to be very effective for the control of mortality rate and approved as a maintenance therapy in asthmatic patients [1, 2]. Budesonide, a corticosteroid used in the first line therapy for coronary obstructive pulmonary disease (COPD), is available in the market as a conventional dry powder inhale (DPI). The optimum dose for budesonide is ranging between 200£¿¦Ìg and 800£¿¦Ìg. This is a potent nonhalogenated corticosteroid having maximum glucocorticoids receptor activity. The hepatic first pass metabolism of budesonide is approximately 90% which is the main reason for its low oral bioavailability of 6¨C11% having half-life 2-3£¿h [3]. The high doses of corticosteroids produce serious side effects upon long-term administration. There is need for controlled release budesonide DPI which could be administered through pulmonary route. Such a formulation could reduce the systemic side effects by achieving high local concentration in the lung and improve the patient compliance [4]. Pulmonary drug delivery system is explored as one of the alternative drug delivery systems due to higher surface area (100¨C140£¿m2), high permeation of lung, avoidance of hepatic first pass metabolism, and noninvasive route for drug administration [5, 6]. It was found to be the most efficient route for treatment of asthma, chronic obstructive pulmonary disease, and cystic fibrosis and now it is being explored for systemic administration of various categories of drug [7]. Drugs used for cancer, diabetes, and migraine could be efficiently administered by this route. Furthermore peptides, proteins, and genes can be administered through this route as these are stable in the dry form [8]. Conventionally dry powder inhalers (DPIs) are prepared by micronization methods which are often blends of fine drug
%U http://www.hindawi.com/journals/jphar/2014/795371/